<DOC>
	<DOC>NCT01843348</DOC>
	<brief_summary>This study is designed to evaluate the renal function comparing Certican based immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant recipients.</brief_summary>
	<brief_title>12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient who has received a primary or secondary kidney transplant Patients who are willing and from whom written informed consent has been obtained kidney allograft with a cold ischemia time (CIT) &lt; 30 hours negative pregnancy test prior to study enrollment Other protocoldefined inclusion/exclusion criteria may apply Other protocoldefined inclusion/exclusion criteria may apply Multiorgan recipients former Graft loss due to immunological reasons Patients receiving a kidney from a nonheart beating donor AB0 incompatible transplants a current Panel Reactive Antibody (PRA) level of &gt; 20% existing antibodies against the HLAtype of the receiving transplant a known hypersensitivity/contraindication to any of the immunosuppressants Use of other investigational drugs Patients with thrombocytopenia (platelets &lt; 100,000/mm³), with an absolute neutrophil count of &lt; 2,000/mm³ or leucopenia (leucocytes &lt; 3,000/mm³), or hemoglobin &lt; 8 g/dL significant mental illness history of malignancy during the last five years HIV positive uncontrolled hypercholesterolemia or hypertriglyceridemia drug or alcohol abuse pregnant or breast feeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>